197 related articles for article (PubMed ID: 19640686)
1. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.
Marchese G; Pittau B; Casu G; Peddio G; Spada GP; Pira M; Deriu A; Portesani F; Pisu C; Lazzari P; Pani L
Eur Psychiatry; 2010 Mar; 25(2):92-100. PubMed ID: 19640686
[TBL] [Abstract][Full Text] [Related]
2. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.
Dremencov E; El Mansari M; Blier P
Psychopharmacology (Berl); 2007 Sep; 194(1):63-72. PubMed ID: 17530476
[TBL] [Abstract][Full Text] [Related]
3. Paliperidone extended release: a review of its use in the management of schizophrenia.
Chwieduk CM; Keating GM
Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
[TBL] [Abstract][Full Text] [Related]
4. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
5. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
Owen RT
Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
[TBL] [Abstract][Full Text] [Related]
8. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone extended-release: does it have a place in antipsychotic therapy?
Gahr M; Kölle MA; Schönfeldt-Lecuona C; Lepping P; Freudenmann RW
Drug Des Devel Ther; 2011 Mar; 5():125-46. PubMed ID: 21448450
[TBL] [Abstract][Full Text] [Related]
10. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481
[TBL] [Abstract][Full Text] [Related]
11. Paliperidone for schizophrenia.
Dolder C; Nelson M; Deyo Z
Am J Health Syst Pharm; 2008 Mar; 65(5):403-13. PubMed ID: 18281731
[TBL] [Abstract][Full Text] [Related]
12. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.
Muly EC; Votaw JR; Ritchie J; Howell LL
J Pharmacol Exp Ther; 2012 Apr; 341(1):81-9. PubMed ID: 22214649
[TBL] [Abstract][Full Text] [Related]
13. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.
Rodríguez-Martínez A; Quilo CG
Clin Drug Investig; 2013 Dec; 33(12):867-76. PubMed ID: 24241935
[TBL] [Abstract][Full Text] [Related]
15. Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.
Richtand NM; Ahlbrand R; Horn P; Stanford K; Bronson SL; McNamara RK
J Psychiatr Res; 2011 Sep; 45(9):1194-201. PubMed ID: 21440257
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
18. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.
van Beijsterveldt LE; Geerts RJ; Leysen JE; Megens AA; Van den Eynde HM; Meuldermans WE; Heykants JJ
Psychopharmacology (Berl); 1994 Feb; 114(1):53-62. PubMed ID: 7531352
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.
Spina E; Cavallaro R
Expert Opin Drug Saf; 2007 Nov; 6(6):651-62. PubMed ID: 17967154
[TBL] [Abstract][Full Text] [Related]
20. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.
Roenker NL; Gudelsky G; Ahlbrand R; Bronson SL; Kern JR; Waterman H; Richtand NM
Neurosci Lett; 2011 Aug; 500(3):167-71. PubMed ID: 21699956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
